lyl797
lyell immunopharmaceutical
['nct05274451', 'lyl797']
plans for a phase 1 clinical trial (nct05274451) for lyl797, an autologous investigational ror1-targeted chimeric antigen receptor (car) t-cell therapy, which has begun screening patients, were detailed in a poster exhibited at #esmo2022 read more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.